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process and identify any implications for manufacturers. Methods: Relevant county 
council and agency websites were used to gather insight into the new NT-rådet evalu-
ation process. A non-systematic literature review was conducted to identify infor-
mation illustrating potential implications of this new process. Results: NT-rådet 
selects in-patient drugs for centralised evaluation and specifies the degree to which 
treatment introduction will be centralised. For high priority treatments, Tandvårds-
och Läkemedelförmånsverket (TLV), will perform a health economic evaluation, upon 
which NT-rådet will base their recommendation, which will be accompanied by a 
monitoring protocol to ensure the organised introduction of treatments to all county 
councils. For low priority treatments, only a health economic evaluation and recom-
mendation will be issued. Any other treatments will go through decentralised reim-
bursement processes. NT-rådet plan to publish recommendations on approximately 
25 products or important indications per year. To date, NT-rådet has issued eight 
recommendations, including one joint recommendation for the use of six Hepatitis 
C therapies. This particular recommendation followed a first of its kind risk-sharing 
agreement between all 21 county councils and industry, which was a key product 
of this new process. ConClusions: The new assessment process has centralised 
the evaluation of some in-patient drugs, but not all. Most new treatments will still 
undergo the decentralised process. Due to its infancy, the impact of the NT-rådet 
process on the uptake of new expensive drugs remains to be confirmed.
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objeCtives: To understand the differences in time to launch between countries 
and the differences in time to reimbursement from launch Methods: We com-
pared time to launch as well as the time to reimbursement from launch of new 
molecular entities granted marketing authorization between 2009 and 2013 across 
18 developed countries. In addition, we conducted a sub-analysis comparing these 
measures for oncology and first-in-class medicines. A comprehensive analysis of the 
regulatory and market access landscapes was also assessed in order to understand 
the reasons behind any differences. Results: A large variation in time to launch of 
all new molecular entities (90 to 430 days) and time to reimbursement from launch 
was observed across studied countries (90 to 540 days). However, countries could be 
classified into three distinct groups: Countries with faster time to launch as well as 
faster time to reimbursement from launch - tended to have regulations mandating 
quick access, especially immediate coverage through public reimbursement after 
regulatory approval (e.g. Germany, Japan). Countries with faster time to launch, but 
slower time to reimbursement - had large private insurance markets but delayed 
public reimbursement negotiations (e.g. Canada). Countries with slower time to 
launch but fast reimbursement after launch - had almost exclusively public reim-
bursement but lengthy public reimbursement negotiations (e.g. France and Italy). 
Among the slower to launch countries, both first-in-class and oncology products 
achieved faster times to launch than the average across all new medicines. There 
was no difference observed in the fast launch countries. ConClusions: Time to 
launch and time to reimbursement from launch in a country is highly dependent 
on local market structure and market access regulations.
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objeCtives: Since 2013, Food and Drugs Administration (FDA) Breakthrough 
Therapy status has enabled expedited development and review of therapies where 
preliminary evidence suggests substantial clinical improvements for serious/life-
threatening conditions. However, there was a pre-existing FDA expedited pathway: 
Accelerated Approval enabling market entry of drugs for serious conditions based 
on a surrogate endpoint likely to predict clinical benefit with confirmatory tri-
als completed post-approval. This abstract aims to compare access of therapies 
under both pathways to determine in which distinct circumstances they are being 
used Methods: All FDA approvals from January 2013-March 2015 were screened 
for any approvals under Breakthrough Status and/or Accelerated Approval and 
the disease areas and supportive data packages were extracted. Results: Since 
November 2013, when the first therapy was approved under Breakthrough sta-
tus, 13 drugs have been FDA-approved under Accelerated Approval and 21 under 
Breakthrough Status including 8 supported by both expedited programs. For the 14 
approvals under Breakthrough Status alone, 11 (79%) were supported by Phase 3 data 
with the remaining 3 (21%) supported by Phase 2. Of the 6 drugs under Accelerated 
Approval alone, 2 (33%) were approved on Phase 3 data with the remaining 4 (66%) 
supported by Phase 2. Of the 7 approved under both programs, only 1 (14%) was 
supported by Phase 3 data, 4 (57%) by Phase 2 data and 2 (29%) by only Phase 1 
data. 86% (12/14) Breakthrough Status alone approvals were for non-oncology drugs 
versus just 16% (1/6) for Accelerated Approval alone and 0% (0/7) for under both pro-
grams. ConClusions: Whereas Accelerated Approval is typically used for oncology 
drugs, Breakthrough Status has been frequently applied to non-oncology medicines. 
Accelerated Approval also frequently enables expedited access without available 
supporting Phase 3 data, unlike Breakthrough Status. Products with supported by 
both programs have gained access supported by only Phase 1 data.
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evaluating, deciding and procuring new technologies. A mini-HTA sheet was tested 
during the interview and questions asked about the relevance and clarity of the 
questions. Results: The current processes of the uptake of technologies is rela-
tively similar in all studied hospitals. There are no standard, transparent evidence 
requirements, nor systems to assess and document the rationales for uptake. The 
clinicians report their needs in free format; the HTA-tools are not know nor used. 
After reducing the number of questions in the mini-HTA-sheet and making some 
changes to its content, order and terminology, the willingness to use increased. 
Information needed for budget impact analysis was considered of particular inter-
est. Procurement officials were strong proponents of systematic and transparent 
assessment. ConClusions: HTA tools need to be tailored to the hospitals. Instead 
of top-down requests for HTA, a low threshold tool is needed to document and 
justify the need of a new technology. This would pave the way for managers with 
financial responsibility to request more thorough assessments. This is the point 
where the new AdHopHTA tools could come in place.
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objeCtives: Telemedicine has been an innovation driver within e-health initiatives 
in health care in recent years. However, the uptake of such initiatives in Germany 
is low. Key question on that is if non-adequate reimbursement/funding might be 
the key reason for the slow introduction of e-health. Methods: We have reviewed 
German e-health initiatives and assessed the requirements for available reimburse-
ment pathways specifically for telemedicine initiatives in Germany and grouped 
them according to the application setting. Results: Overall there are currently 289 
e-health initiatives implemented in Germany in only few centers (mainly Berlin, Bad 
Oeynhausen, Munich, Hamburg). Telemedicine is being handled as medical devices 
in Germany within the market access pathway. The exact process depends if the 
device is an inpatient or outpatient product. In the inpatient setting relevant DRG 
and OPS codes are applicable; theoretically NUB and additional fee (Zusatzentgelt) 
could also be applied for. In the outpatient setting, the reimbursement of e-health 
devices is driven through the respective catalogue of aids and appliances whereas 
the actual physician service would need to be reimbursed through the EBM 
(Einheitlicher Bewertungsmassstab). Currently there is no specific EBM code avail-
able, and health politicians have missed a deadline in 2014 to create one. Besides the 
self-payment option as individual physicians services (IGeL) there is the opportunity 
through selective contracts, particularly Disease Management Programs (DMPs) or 
integrated care contracts. Most telemedicine projects are currently being covered 
and tested in the latter ones (e.g. telemonitoring CHF, video Parkinson therapy). An 
alternative new route could also be the experimental coverage by the joint federal 
committee. ConClusions: Currently the most relevant market access pathway 
for telemedicine initiatives in Germany is through selective contracts. Once health 
politicians put e-health as a priority the introduction of specific DRG and EBM 
codes could initiate fast adaption and more telemedine introductions in Germany.
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objeCtives: The British Isles comprise 4 countries, each with their own distinct 
Health Technology Assessment (HTA) body: National Institute of Health and Care 
Excellence (NICE) in England, National Centre for Pharmacoeconomics (NCPE) in 
Ireland, Scottish Medicines Consortium (SMC) in Scotland and All Wales Medicines 
Strategy Group (AWMSG) in Wales. Although all four bodies are obligate cost-utility 
HTA agencies, they do utilise distinct assessment processes. This research aims to 
compare the number and type of appraisals and recommendation rates between 
these bodies during 2014. Methods: All publically available NICE Single Technology 
Appraisal, SMC, NCPE and AWMSG HTA reports were identified in 2014 and the drug, 
indication and outcome extracted. Results: NCPE conducted the greatest number 
of appraisals (60) followed by the SMC (52), NICE (29) and the AWMSG (25). However, it 
should be noted that 68% of NCPE appraisals were through its rapid review pathway 
(not needing a full pharmaco-economic assessment). The highest rate of positive full 
recommendations was made by NICE (86%), followed by AWMSG (84%), SMC (79%), 
and the NCPE (39%). However, there was variation in what proportions of these 
recommendations were for a restricted sub-population: SMC (47%), AWMSG (29%), 
NICE (15%) and NCPE (5%). The proportion of oncology drugs appraised was highest 
by NICE (37%) followed by NCPE (37%), SMC (21%) and AWMSG (4%). ConClusions: 
The NCPE reviewed the greatest number of medicines but also had by far the highest 
rejection rates. Although NICE, AWMSG, and SMC had similar acceptance rates, the 
SMC displayed a greater propensity to restrict indications, and AWMSG (and to a 
lesser extent the SMC) reviewed a low number of oncology drugs, typically high cost 
agents that have greater difficulties in attaining positive reimbursement decisions. 
Thus it appears that in 2014 NICE appeared to be the most generous HTA body in 
awarding positive recommendations!
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objeCtives: The decision to fund an in-patient drug is currently made on a regional 
level by formulary committees in each of the 21 Swedish county councils. A pilot 
project for a centralised route of assessment for expensive, new in-patient treatments 
was replaced by a permanent body, Nya Terapier Rådet (NT-rådet), for centralised 
evaluation in January 2015. The objective of this research is to understand this new 
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tion, where MoH achieves equity principles by enhancing access to medicine among 
the poor, while pharmaceutical companies launch their products in the Egyptian 
market, with an acceptable return to their investments.
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objeCtives: Japan is a low generic adoption market, and increased penetration has 
become a critical target to generate savings to fund innovative drugs and control 
healthcare expenditure. The objective of this research was to provide an overview 
of policies implemented in Japan to boost generics uptake and to assess impact of 
these measures. Methods: Generics policies and uptake were identified through 
literature review from: Japanese authority website, Japan Generics Association 
website, Medline®, ICHUSHI® database and grey literature. Results: Generics 
policies have been implemented in Japan since 2002. In 2002, the National Health 
Insurance (NHI) medical fee schedule introduced financial incentives to prescribe 
generic drugs for providers (pharmacies and hospitals). Since then, various financial 
incentives to providers have been introduced by the biannual revision of NHI medi-
cal fee schedule. Diagnostic Procedure Classification system (bundled payment) 
encouraging generic drug use was introduced in acute care hospitals in 2003 and 
expanded to 21% of general hospitals (55% of hospital beds) in 2014. In 2007, the 
government put in place an action plan to encourage generic drug use. This was 
complemented in 2013 by a roadmap aiming at increased generic penetration to 
exceed 60% by 2018. More aggressive financial incentives were introduced in April 
2014 setting up generic volume threshold for pharmacies. The generic market share 
was continuously increased from 32.5% (2005), 39.9% (2011), to 47.9% (2013), and 
rapidly increased from 51.2% (March 2014) to 57.1% (November 2014). The recent 
policy accelerating the generic market share targeting at least 70% by 2017 is under 
discussion at the economic advisory council and raise concern about excessive 
speed. ConClusions: The recent health policy measures to increase generics 
uptake confirm this priority for policy decision makers in Japan. Following recent 
aggressive policies the Japanese generic market will soon match other developed 
countries.
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objeCtives: Regarding the discussion on AMNOG in Germany that for certain 
diseases it might be more difficult to prove an additional benefit (AB) than for 
other ones, a respective analysis of benefit assessments was conducted consider-
ing the following disease categories: Chronic conditions, cancer, and infectious 
diseases. Methods: In total, 91 benefit assessments finalized until 31 December 
2014 (except for drugs integrated into an existing reference price group) and entail-
ing 182 patient groups (PG) were analyzed. Results: A total of 41 benefit assess-
ments regarding chronic conditions entailing 89 PG (of which 52 were part of 
antidiabetic drug assessments) were conducted. An AB vs. the appropriate com-
parator could not be proven for 83% of PG. For antidiabetic drugs, this number even 
amounted to 90% (47 of 52 PG). A considerable AB was granted for only 2% of PG 
(Ticagrelor for NSTEMI patients and Belimumab for systemic lupus erythematosus 
with high disease activity). As opposed to chronic conditions, the proportions 
of PG without any AB were only 46% and 39% in cancer and infectious diseases, 
respectively. A considerable AB was granted for 28% und 18% of PG, respectively. In 
terms of assessments, no AB was granted for any PG in case of 30 (73%) out of 41 
benefit assessments regarding drugs for chronic conditions (including 11 out of 15 
assessments for antidiabetic drugs). As opposed to this, there was no AB acknowl-
edged in only 3 (27%) out of 11 assessments on drugs against infectious diseases 
and in only 5 (22%) out of 23 assessments on anticancer drugs. ConClusions: 
There seems to be a correlation between disease category and the chance of AB 
recognition. Reasons for this could be the choice of an appropriate comparator 
as well as issues regarding patient-relevant endpoints. These results could be 
relevant discussing the further development of AMNOG.
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objeCtives: the aim of this study was to identify the cohort of patients starting 
treatment with biologics in the years 2012-2013 and estimate the number of patients 
that switch therapy within the first 12 months. Methods: Patients were enrolled 
based on data extrapolated from the File F and H- OSP File (Administrative data-
base) of the Lazio region (central region in Italy). The treatment-naïve patients has 
been defined as individuals who did not have a prescription in the two years before 
the index prescription. Patients that switch biologic therapy have been defined 
as therapeutic prescription different than Anatomical Therapeutic Chemical clas-
sification (ATC) of enrollment within one year of the index date. Biologic drug, 
hospitalization and concomitant drug cost have been included in the analysis. The 
information sources were linked with a deterministic record linkage and the patho-
logical condition was inferred from the treatment plan prescription of the Lazio 
Region. Results: From a total number of 33,027 patients treated with biologic 
drug between 2010-2014 in the Lazio region, it were estimated 3,002 treatment-
naïve patients (43% male). The most frequent prescription was related to Etanercept 
(974 patients, 32%), adalimumab (898 patients, 30%) and infliximab (524 patients, 
objeCtives: The National Committee for Technology Incorporation (CONITEC) aims 
to support Ministry of Health in decisions on incorporation, exclusion or modi-
fication of technologies in the Brazilian Public Health System (SUS). For this, it 
produces reports with recommendations with different characteristics. To analyze 
the CONITEC reports on incorporation, exclusion or modification of health technolo-
gies in the SUS. Methods: Descriptive study, based on the reports available at the 
CONITEC website, from July 2012 to April 2015. Reports were classified according to: 
type of technology, type of applicant, type of report, presence of Health Economic 
Evaluation (HEE), and the type of HEE. Results: One hundred and thirty two reports 
were analyzed. The type of technologies most frequently evaluated were: drugs 
(65.2%), procedures (19.7%) and materials (9.1%). The two major applicants were: 
Public Health System (51.5%) and pharmaceutical industry (37.1%). The majority of 
reports were classified as: Description of Technology (40%), Mini Health Technology 
Assessment (33%), Rapid Review (23%) and only 4% of the reports were Full Health 
Technology Assessment. One hundred and one reports studies included some eco-
nomic data, 53.5% (n = 54) were classified as partial HEE and 46.5% (n = 47) were 
full HEE. Among partial economic evaluation, initial estimates of budget impact 
analysis was the most frequent (n = 51; 94.4%) and among the full economic evalu-
ations, cost-effectiveness analysis (n = 20; 42.6%). Out of 47 full economic evalua-
tions, 33 (70.2%) presented the incremental cost-effectiveness ratios (ICERs). Of all 
the analyzed reports (n = 132), only 25% (n = 33) performed a complete HEE with 
ICER. ConClusions: The type of technologies most frequently evaluated were 
drugs, and the major applicant was the Public Health System. The majority of the 
recommendations were based on Technology Description reports, and the most 
common HEE was initial estimates of budget impact analysis.
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objeCtives: CONITEC has recommended for incorporation part of the technolo-
gies analyzed. Among the requested documents, applicants must provide a Health 
Economic Evaluation (HEE) under the SUS perspective, including an incremental 
cost-effectiveness ratio (ICER). However in the legal documents there is no explicit 
recommendation on the use of ICER and cost-effectiveness threshold (CET) as a 
criteria for technology recommendation. To analyze the CONITEC reports that 
recommended the incorporation of the technologies in the SUS from July 2012 to 
April 2015, and compare the values of the ICERs with CETs suggested in the litera-
ture. Methods: Descriptive study, based on the reports available at the CONITEC 
website from July 2012 to April 2015. Reports were classified according to: type of 
technology, type of applicant, type of report, presence of HEE, and the type of HEE. 
ICER was compared with the CET recommended by WHO and Center of Health 
Economics (CHE)-University of York. Results: Seventy-two reports recommended 
the incorporation of the technology in the SUS. The most common technologies 
recommended were drugs (51.4%), procedures (30.6%) and materials (8.3%). The 
major applicant was the Public Health System (70.8%), followed by the pharmaceuti-
cal industry (8.3%). Most reports were classified as Technology Description (65.3%), 
followed by Rapid Review (19.4%), Mini Health Technology Assessment (8.3%), and 
only 6.9% the reports were Full HTA. Fifty-five reports conducted HEE, 80% (n = 
44) were partial and 20% (n = 11) were full. Of the Seventy-two technologies rec-
ommended for incorporation, only 8(11.1%) presented a full HEE with ICER. Seven 
technologies presented ICER below the CET proposed by WHO and only one below 
the CET proposed by CHE. ConClusions: Most of the technologies recommended 
for incorporation were demanded by the Public Health System and were based on 
Technology Descriptions and Rapid Reviews. Use of a CET was not an essential 
criterion for recommending technology incorporation.
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intRoduCtion: Egypt healthcare system shows high Out-Of-Pocket (OOP) expendi-
ture on health (72% of THE), with 40% of total OOP dedicated to pharmaceuticals. 
In an attempt to maintain patient access to affordable medicines, the Egyptian 
Ministry of Health (MoH) implements a strict pricing policy for pharmaceuticals. 
However, the current pricing system has some drawbacks and challenges. These 
challenges often cause delays in launch of some innovative medicines, shortage 
in some important medicines and dissatisfaction of the pharmaceutical industry 
about the low prices that put a great pressure on their operational sustainabil-
ity. Consequently the MoH decided to introduce some reform actions to address 
these problems, aiming to achieve fair pricing policy, using the differential pricing 
concept. objeCtives: To explore different Methods of differential pricing within 
a country, to evaluate their applicability for Egypt by taking into account the inter-
national price referencing framework, and to provide recommendations for fair 
pricing of pharmaceuticals in Egypt. Methods: A focus group of decision makers 
and industry experts was established to discuss the possible pricing options within 
the Egyptian healthcare system context and develop core assumptions before pre-
paring a draft report. The recommendations were developed by using the Quasi-
Delphi method. Results: Innovative pricing models, like differential pricing with 
confidential agreements, are expected to 1) shift the financial burden of pharma-
ceuticals’ price to the more affluent consumers and distribute the cost of innovation 
across the patients according to their socio-economic status, and 2) reduce negative 
externalities related to the international reference pricing system. ConClusions: 
Differential pricing with confidential agreements would achieve a win-win situa-
